Gritstone Bio Pre-Tax Profit Margin 2017-2024 | GRTSQ
Gritstone Bio pre-tax profit margin from 2017 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
Gritstone Bio Pre-Tax Profit Margin Historical Data |
Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
2024-06-30 |
$0.02B |
$-0.13B |
-880.00% |
2024-03-31 |
$0.02B |
$-0.14B |
-900.00% |
2023-12-31 |
$0.02B |
$-0.14B |
-862.50% |
2023-09-30 |
$0.01B |
$-0.14B |
-1380.00% |
2023-06-30 |
$0.01B |
$-0.13B |
-1181.82% |
2023-03-31 |
$0.01B |
$-0.13B |
-892.86% |
2022-12-31 |
$0.02B |
$-0.12B |
-631.58% |
2022-09-30 |
$0.02B |
$-0.12B |
-661.11% |
2022-06-30 |
$0.02B |
$-0.12B |
-650.00% |
2022-03-31 |
$0.02B |
$-0.11B |
-700.00% |
2021-12-31 |
$0.05B |
$-0.08B |
-153.06% |
2021-09-30 |
$0.05B |
$-0.07B |
-153.19% |
2021-06-30 |
$0.05B |
$-0.07B |
-155.56% |
2021-03-31 |
$0.04B |
$-0.07B |
-169.05% |
2020-12-31 |
$0.00B |
$-0.11B |
-3500.00% |
2020-09-30 |
$0.00B |
$-0.11B |
-3533.33% |
2020-06-30 |
$0.00B |
$-0.11B |
-3600.00% |
2020-03-31 |
$0.00B |
$-0.10B |
-2575.00% |
2019-12-31 |
$0.00B |
$-0.10B |
-2375.00% |
2019-09-30 |
$0.00B |
$-0.08B |
-2100.00% |
2019-06-30 |
$0.00B |
$-0.08B |
-2500.00% |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|